AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Good morning, and welcome to the Axsome Therapeutics Fourth Quarter and Full Year 2024 Conference Call. Currently, all participants are in a listen-only mode. Later, there will be a ...

With a new product announcement coming on Wednesday, investors might be wondering: Is Apple stock a buy right now?

A woman has been arrested on suspicion of driving under the influence after she was involved in a crash that claimed the life ...

Brookfield Corporation (NYSE: BN) has been a top-performing stock over the decades. The leading global investment manager has ...

Alvotech (NASDAQ:ALVO) and Teva Pharmaceuticals (NYSE:TEVA) said on Tuesday that the U.S. FDA has accepted for review a ...

Declares Dividend Increase for 69th Consecutive YearProvides 2025 Outlook Fourth Quarter 2024 Highlights Sales of $5.8 billionDiluted EPS of $0.96Adjusted Diluted EPS of $1.61Full-Year 2024 Highlights ...